ArticleThe European respiratory journal2018
Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement.
Registry-linked trialAbstract readConsensus Statement
In one paragraph
Article in The European respiratory journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05824988 (Drug Exposure and Minimum Inhibitory Concentration in the Treatment of Mycobacterium Avium Complex Lung Disease), which is not on this map. Cited by 143 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
143citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Drug Exposure and Minimum Inhibitory Concentration in the Treatment of Mycobacterium Avium Complex Lung Disease: a Prospective Observational Cohort Study
Who cites it
143 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Guideline
- Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.The European respiratory journal · 2020Guideline
- Omadacycline Monotherapy in Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium abscessus: Results From a Phase 2, Double-blind, Randomized, Placebo-controlled Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Trial
- Treatment Outcomes ofOpen forum infectious diseases · 2025Trial
- Effect of Individual Agents on Time to Culture Conversion inOpen forum infectious diseases · 2025Trial
- Amikacin Liposome Inhalation Suspension forAnnals of the American Thoracic Society · 2021Trial
- Immediate Treatment Versus Watchful Waiting in Mycobacterium avium Complex Pulmonary Disease: A Propensity Score Matched Analysis.Infectious diseases and therapy · 2026Article
- Efficacy and safety of an intravenous amikacin-containing regimen as initial therapy inJournal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- Performance of the BACES model in a Dutch cohort with nontuberculous mycobacterial pulmonary disease.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- Radiographic severity and treatment optimisation inERJ open research · 2026Article
- Exposure to azithromycin and the effect of co-administration of rifampicin in patients with non-tuberculous mycobacterial disease.The Journal of antimicrobial chemotherapy · 2026Article
- Treatment outcomes of Mycobacterium simiae pulmonary disease: a retrospective multicenter cohort study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Targeting Inflammation in Bronchiectasis.Drugs · 2026Review
- A single-centre analysis of the clinical characteristics of non-tuberculous mycobacterial lung disease caused by rare species.IJTLD open · 2026Article
- Real-World Experience of Prolonged Treatment for Treatment-Refractory Nontuberculous Mycobacterial Pulmonary Disease: Benefits and Harms of Extending Therapy beyond 24 Months.Respiration; international review of thoracic diseases · 2026Article
- Understanding recurrence inJournal of clinical microbiology · 2026Review
- Association between nutritional status and clinical characteristics in nontuberculous mycobacterial pulmonary disease: preliminary results from the NTM-KOREA cohort.Respiratory research · 2026Article
- Clinical characteristics of pulmonary non-tuberculous mycobacterial disease withBMJ open respiratory research · 2026Article
- Patient's features, clinical patterns and outcomes of non-tuberculous mycobacteria infections: A 10-year retrospective analysis from a third level university hospital.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- Article
83 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Jakko van IngenDept of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands Jakko.vaningen@radboudumc.nl.ORCID 0000-0002-0581-2003
Timothy AksamitDivision of Pulmonary and Critical Care Medicine, Dept of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Claire AndrejakRespiratory and Intensive Care Unit, University Hospital Amiens, Amiens, France.
Erik C BöttgerInstitute of Medical Microbiology, National Reference Center for Mycobacteria, University of Zurich, Zurich, Switzerland.
Emmanuelle CambauNational Reference Center for Mycobacteria and Antimycobacterial Resistance, APHP, Hôpitaux universitaires Saint Louis-Lariboisière-Fernand Widal, Bacteriology, Paris, France.
Charles L DaleyDivision of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, CO, USA.
David E GriffithPulmonary Infectious Disease Section, University of Texas Health Science Center, Tyler, TX, USA.
Lorenzo GuglielmettiAPHP - Hôpital Lariboisière, Service de Bactériologie, Centre National de Référence des Mycobactéries et de la résistance des Mycobactéries aux Antituberculeux, Paris, France.ORCID 0000-0003-0886-9635
Steven M HollandDivision of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Gwen A HuittDivision of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, CO, USA.
Won-Jung KohDivision of Pulmonary and Critical Care Medicine, Dept of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.ORCID 0000-0002-4756-3527
Christoph LangeDivision of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.
Philip LeitmanNTM Info & Research, Miami, FL, USA.
Theodore K MarrasDept of Medicine, University of Toronto and University Health Network, Toronto, ON, Canada.
Kozo MorimotoDivision of Clinical Research, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.
Kenneth N OlivierPulmonary Branch, National Heart, Lung and Blood Institute, Bethesda, MD, USA.
Miguel SantinService of Infectious Diseases, Bellvitge University Hospital-IDIBELL, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
Jason E StoutDivision of Infectious Diseases and International Health, Duke University Medical Center, Durham, NC, USA.
Rachel ThomsonGallipoli Medical Research Centre, University of Queensland, Brisbane, Australia.
Enrico TortoliEmerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Richard J WallaceMycobacteria/Nocardia Laboratory, Dept of Microbiology, The University of Texas Health Science Center, Tyler, TX, USA.
Kevin L WinthropDivisions of Infectious Diseases, Public Health and Preventive Medicine, Oregon Health and Science University, Portland, OR, USA.
Dirk WagnerDivision of Infectious Diseases, Dept of Medicine II, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
for NTM-NET
Funding
Bronchiectasis and chronic airway infectionZIAHL006200 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI FENNELLY, KEVIN · 2015 to 2025
$25.1MGenes And Gene Products As ImmunoadjuvantsZIAAI000647 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI HOLLAND, STEVEN · 2009 to 2025
$22.6MTransgenic Animal Models Of Human Immune DefectsZIAAI000646 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI HOLLAND, STEVEN · 2009 to 2025
$22.2MIntramural NIH HHS ZIA HL006200
Abstract
PubMed holds no abstract for this paper.
Indexed as
Lung DiseasesMycobacterium Infections, NontuberculousNontuberculous MycobacteriaPulmonary MedicineHumansInternational CooperationLungSocieties, MedicalTreatment Outcome
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT05824988ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.